Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) saw unusually-strong trading volume on Wednesday. Approximately 332,235 shares traded hands during mid-day trading, a decline of 11% from the previous session’s volume of 372,680 shares. The stock last traded at $32.82 and had previously closed at $32.60.
Wall Street Analyst Weigh In
COAG has been the subject of several recent analyst reports. Wedbush boosted their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Jefferies Financial Group increased their price target on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday. Finally, HC Wainwright upped their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Hemab Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $51.40.
Read Our Latest Research Report on COAG
Hemab Therapeutics Stock Performance
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Analysts forecast that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of COAG. Citadel Advisors LLC acquired a new position in Hemab Therapeutics in the 2nd quarter valued at $19,226,000. Braidwell LP purchased a new stake in Hemab Therapeutics during the second quarter worth $5,877,000. State Street Corp acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth $2,825,000. Opaleye Management Inc. purchased a new stake in shares of Hemab Therapeutics in the 2nd quarter worth about $1,750,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Hemab Therapeutics in the 2nd quarter worth about $688,000.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.
Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.
Featured Stories
- Five stocks we like better than Hemab Therapeutics
- 3 Healthcare Dividend Stocks Offering More Than Just Income
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
- Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
